Abstract
Objectives Post-COVID syndrome remain poorly studied in children and adolescents. In this study, we aimed to investigate the prevalence and risk factors of pediatric post-COVID in a population-based sample, stratifying by serological status.
Study design We used data from the SEROCoV-KIDS cohort study (State of Geneva, Switzerland), which included children (aged 6 months to 17 years) selected from random samples drawn from state registries or who had a household member participating in a COVID-19 seroprevalence study conducted by our group. Children were tested for anti-SARS-CoV-2 N antibodies. Parents filled in a questionnaire on persistent symptoms in their children (lasting over 12 weeks) compatible with post-COVID syndrome.
Results From December 1st, 2021 to February 16th, 2022, 1034 children were included, among whom 570 (55.1%) were seropositive. The sex- and age-adjusted prevalence of persistent symptoms among seropositive children was 9.1% (95%CI: 6.7;11.8) and 5.0% (95%CI: 3.0;7.1) among seronegatives, with an adjusted prevalence difference (ΔaPrev) of 4.1% (95%CI: 1.1;7.3). After stratification by age group, the prevalence was higher among adolescents aged 12-17 years (ΔaPrev=8.3%, 95%CI: 3.5;13.5) than among younger children (0.0%, 95%CI: −5.2;5.2 among 6-11 years old and 4.2%; 95%CI: −4.4;13.3 among 0-5 years old). The most frequently declared persistent symptoms among seropositives were smell loss, trouble concentrating and abdominal pain. Older age, having a chronic condition and lower socioeconomic conditions were identified as risk factors.
Conclusion A significant proportion of seropositive children, particularly adolescents, experienced persistent symptoms. While there is a need for further investigation, growing evidence of pediatric post-COVID syndrome urges early screening and primary care management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Fundings The project is partially funded by the Jacobs Foundation, and partially funded by the FOPH. The Jacobs Foundation and the FOPH are supporting the project for a 36 and 18 months, respectively.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Geneva Cantonal Commission for Research Ethics approved this study (ID 2021-01973).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Fundings The project is partially funded by the Jacobs Foundation, and partially funded by the FOPH. The Jacobs Foundation and the FOPH are supporting the project for a 36 and 18 months, respectively.
Conflict of interest None of the funding institutions participated in the conduct of the research or in the preparation of the article.
Data Availability Our data are accessible to researchers upon reasonable request for data sharing to the corresponding author.
Data Availability
Our data are accessible to researchers upon reasonable request for data sharing to the corresponding author.
List of abbreviations
- ΔaPrev
- adjusted Prevalence Difference
- aPrev
- adjusted Prevalence
- aPR
- adjusted Prevalence Ratio
- CI
- Confidence interval
- COVID-19
- Coronavirus disease 2019
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
